drugset / Trial / NCT00947375
Lamictal TM, Haloperidol Decanoate in Schizophrenia
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine the effect of lamotrigine augmentation of Haloperidol decanoate in the treatment of Resistant Schizophrenia predominantly by verbal resistant hallucinosis: A randomized, double-blind, placebo-controlled, study. Nadir A.Aliyev \& Zafar N.Aliyev Central Mental Clinic for Outpatients of Baku city of Azerbaijan Republic Abstract: OBJECTIVE: The current paper reports on a double-blind, randomized study of the role of lamotrigine as an augmentation agent to haloperidol decanoate in the treatment of out patient's schizophrenia with verbal resistant hallucinosis.
Timeline
- Start
- 2005-01
- Primary completion
- 2006-01
- Completion
- 2007-01
Outcome
Outcome not reported
Stopped: “All of the mentioned aim and objectives were achieved before the February 2007”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lamotrigine | Small molecule | 150 mg | Oral |
| Subject | Lamotrigine | Small molecule | 200 mg | Oral |
| Background | Haloperidol Decanoate | Small molecule | 50 mg | Intramuscular |